NFKB1 and cancer: Greiner and colleagues described, for the first time, a significant downregulation of inflammatory processes via decreased activities of transcription factor NFκB and the JNK (c-Jun N-terminal kinase)/AP-1 (activator protein-1) pathway in the human cancer cell lines U373 and HeLa in response to 1,8-Cineol, the active ingredient of the drug Soledum®.